Larimar director buys 5,000 shares in offering

Q: What insider transaction did Larimar Therapeutics (LRMR) report for Jeffrey W. Sherman?

Larimar Therapeutics reported that director Jeffrey W. Sherman bought 5,000 shares of common stock. The purchase was made at $5.00 per share in an underwritten offering that closed on February 27, 2026.

Q: At what price did the Larimar Therapeutics director buy shares?

Director Jeffrey W. Sherman purchased Larimar Therapeutics common stock at $5.00 per share. This price reflects the offering price in the company’s underwritten stock offering, which closed on February 27, 2026, according to the Form 4 footnote.

Q: How many Larimar Therapeutics shares does Jeffrey W. Sherman hold after this Form 4 transaction?

After this Form 4 transaction, director Jeffrey W. Sherman is reported as directly owning 5,000 shares of Larimar Therapeutics common stock. The filing shows these shares were acquired in the company’s underwritten offering that closed on February 27, 2026.

Q: Was the Larimar Therapeutics insider purchase part of an underwritten offering?

Yes. The Form 4 footnote states the 5,000 common shares were purchased in an underwritten offering of Larimar Therapeutics at the offering price. That offering closed on February 27, 2026, and the shares are held directly by director Jeffrey W. Sherman.

Q: Is Jeffrey W. Sherman a director or officer at Larimar Therapeutics (LRMR)?

Jeffrey W. Sherman is identified in the Form 4 as a director of Larimar Therapeutics. He is not listed as an officer in this filing and does not report ten percent owner status, but does report direct ownership of 5,000 common shares after the transaction.

Larimar Therapeutics director Jeffrey W. Sherman bought 5,000 shares of the company’s common stock at $5.00 per share in an underwritten offering that closed on February 27, 2026.

Filing Impact

(Neutral)

Filing Sentiment

(Positive)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Larimar Therapeutics director Jeffrey W. Sherman bought 5,000 shares of the company’s common stock at $5.00 per share in an underwritten offering that closed on February 27, 2026. The transaction is reported as a direct, open-market style purchase on a Form 4 insider filing.

Insider Trade Summary

Net Buyer: 5,000 shares

Net Buy 1 txn

Insider SHERMAN JEFFREY W

Role Director

Bought 5,000 shs ($25K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	5,000	$5.00	$25K

Holdings After Transaction: Common Stock — 5,000 shares (Direct)

Footnotes (1)

F1. Represents shares of common stock purchased in the underwritten offering of Larimar Therapeutics, Inc. at the offering price, which closed on February 27, 2026.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Larimar Therapeutics (LRMR) report for Jeffrey W. Sherman?

Larimar Therapeutics reported that director Jeffrey W. Sherman bought 5,000 shares of common stock. The purchase was made at $5.00 per share in an underwritten offering that closed on February 27, 2026.

At what price did the Larimar Therapeutics director buy shares?

Director Jeffrey W. Sherman purchased Larimar Therapeutics common stock at $5.00 per share. This price reflects the offering price in the company’s underwritten stock offering, which closed on February 27, 2026, according to the Form 4 footnote.

How many Larimar Therapeutics shares does Jeffrey W. Sherman hold after this Form 4 transaction?

After this Form 4 transaction, director Jeffrey W. Sherman is reported as directly owning 5,000 shares of Larimar Therapeutics common stock. The filing shows these shares were acquired in the company’s underwritten offering that closed on February 27, 2026.

Was the Larimar Therapeutics insider purchase part of an underwritten offering?

Yes. The Form 4 footnote states the 5,000 common shares were purchased in an underwritten offering of Larimar Therapeutics at the offering price. That offering closed on February 27, 2026, and the shares are held directly by director Jeffrey W. Sherman.

Is Jeffrey W. Sherman a director or officer at Larimar Therapeutics (LRMR)?

Jeffrey W. Sherman is identified in the Form 4 as a director of Larimar Therapeutics. He is not listed as an officer in this filing and does not report ten percent owner status, but does report direct ownership of 5,000 common shares after the transaction.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 03/02/2026 - 04:30 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

SHERMAN JEFFREY W

(Last)

(First)

(Middle)

C/O LARIMAR THERAPEUTICS, INC.

THREE BALA PLAZA EAST, SUITE 506

(Street)

BALA CYNWYD

19004

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Larimar Therapeutics, Inc. [ LRMR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/27/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	02/27/2026		P		5,000⁽¹⁾	A	$5	5,000	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Represents shares of common stock purchased in the underwritten offering of Larimar Therapeutics, Inc. at the offering price, which closed on February 27, 2026.

	/s/ Jennifer Johansson, Attorney-in-fact	03/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR